Unlikely to cause harm — often a labeling or packaging issue.
Failed Dissolution Specifications; during stability testing
| Brand name | BUPROPION HYDROCHLORIDE (SR) |
| Generic name | BUPROPION HYDROCHLORIDE |
| Active ingredient(s) | BUPROPION HYDROCHLORIDE |
| Distributed by / for | Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323 |
| NDC | 69097-878-03 |
| Full product label | buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 69097-878-03) and b) 100 count (NDC 69097-878-07) bottles, Rx Only, Manufactured for: Cipla USA Inc. 1560 Sawgrass Corporate Parkway Suite 130 Sunrise, FL 33323, Manufactured by: InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Ltd.) Hauppauge, NY 11788 |
| Recalling firm | InvaGen Pharmaceuticals, Inc. |
| Distribution | Nationwide |
| Quantity | N/A |
| Recall initiated | 2018-03-15 |
| Report date | 2018-04-11 |
| Recall completed | 2021-09-15 |
| Recall number | D-0619-2018 |
| Classification | Class III |
| FDA status | Terminated |
| Origin on file | Hauppauge NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗